Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with resiquimod may make a stronger immune response and prevent or delay the recurrence of cancer.

PURPOSE: This clinical trial is studying the side effects, best dose, and best way to give vaccine therapy together with resiquimod in treating patients with stage II, stage III, or stage IV melanoma that has been completely removed by surgery.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Cancer Institute (NCI)

Criteria

DISEASE CHARACTERISTICS:

• Prior diagnosis of melanoma meeting the following criteria:

• Stage II-IV disease

• Complete resection of disease

• No current evidence of disease

• HLA-A2 positive

• No known standard therapy for disease that is potentially curative or proven capable of extending life expectancy exists

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Hemoglobin ≥ 9.0 g/dL

• Platelet count ≥ 75,000/mm³

• AST ≤ 3 times upper limit of normal

• No uncontrolled or current infection

• No known allergy to vaccine or adjuvant components

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No known immune deficiency

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• More than 4 weeks since prior chemotherapy and recovered

• More than 4 weeks since prior biologic therapy

• No concurrent immunosuppressive therapy